Efficacy Trial for the Reduction of Glabellar Lines

Sponsor
Serene Medical Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT02466178
Collaborator
(none)
78
5
22
15.6
0.7

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the ability of the Serene RF System to effectively improve the appearance of dynamic glabellar lines and sustain the effect for a minimum of 3 months.

Condition or Disease Intervention/Treatment Phase
  • Device: Serene RF System

Study Design

Study Type:
Observational
Actual Enrollment :
78 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Multicenter Efficacy Trial of the Serene RF System for the Reduction of Glabellar Lines
Study Start Date :
Feb 1, 2015
Actual Primary Completion Date :
Apr 1, 2016
Actual Study Completion Date :
Dec 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Serene RF System

Percutaneous delivery of radiofrequency (RF) energy to create a temporary conduction block to the corrugator and/or procerus muscles.

Device: Serene RF System
The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.

Outcome Measures

Primary Outcome Measures

  1. The reduction of glabellar lines [3 months]

    The reduction of glabellar lines will be assessed by a panel of 3 independent reviewers with expertise in dermatology and/or plastic surgery of the change in glabellar lines measured from baseline to 3, 6, 9 and 12 months post procedure. Photographs will be presented in a random order and the reviewers will be blinded to whether the photograph is baseline or a follow up. Effectiveness of the procedure is defined by a ≥ 1 point improvement in score (i.e., numerical decrease) on the Mertz Aesthetics Scale™ (Merz Scale) for dynamic glabellar lines. At each time point the severity of the glabellar lines is assessed on a 5 point scale.

Secondary Outcome Measures

  1. Incidence and severity of adverse events [3 months]

  2. The reduction of glabellar lines [12 months]

    The reduction of glabellar lines will be assessed by a panel of 3 independent reviewers with expertise in dermatology and/or plastic surgery of the change in glabellar lines measured from baseline to 3, 6, 9 and 12 months post procedure. Photographs will be presented in a random order and the reviewers will be blinded to whether the photograph is baseline or a follow up. Effectiveness of the procedure is defined by a ≥ 1 point improvement in score (i.e., numerical decrease) on the Mertz Aesthetics Scale™ (Merz Scale) for dynamic glabellar lines. At each time point the severity of the glabellar lines is assessed on a 5 point scale.

  3. Subject satisfaction [12 months]

    Subject satisfaction will be assessed by a survey given every 3 months. This survey asks the subject questions to rate on a scale of 0-4 with 0 representing very dissatisfied and 4 representing very satisfied.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Glabellar lines rating of at least two per the Merz Scale

  2. Written informed consent

  3. Understands and accepts the following obligations during the follow-up period (minimum of three months and up to one year)

  4. available for the 3 day phone call and present for each follow-up visit;

  5. receive NO other facial procedures in the upper face for a minimum of three months and up to one year after the RF procedure;

  6. make NO changes to the eyebrows for a minimum of three months after the RF procedure.

Exclusion Criteria:
  1. Injection of botulinum toxin to the upper face within the previous four months

  2. Use of fillers in the upper face within the previous twelve months

  3. Use of prescription treatments (e.g., Renova, Retin-A, micro-dermabrasion, chemical peels) on the upper face, in the area between the eyebrows where frown lines occur, within the previous four weeks or plans to use these treatments during the study

  4. Facial or skin conditions that could interfere with treatment or confound results (e.g., signs or symptoms of eyebrow or eyelid ptosis, facial nerve palsy, scarring, infection)

  5. Implanted pacemaker or automatic implantable cardioverter/defibrillator

  6. History of keloid formation

  7. Known bleeding disorder

  8. Use of thrombolytics, anticoagulants, aspirin or non-steroidal anti-inflammatory drugs within seven days prior to study treatment Is receiving systemic corticosteroids or anabolic steroids (standard doses of inhaled or nasal corticosteroids are acceptable)

  9. History of chronic or recurrent infection, or compromised immune system

  10. Known lidocaine hypersensitivity

  11. Enrollment in another research study

  12. Pregnant, or plans to get pregnant during the follow-up period

  13. Any other condition or circumstance that might either pose a risk, in the investigator's opinion, to the subject or interfere with the ability to acquire satisfactory clinical data throughout the follow-up period

Contacts and Locations

Locations

Site City State Country Postal Code
1 Premier Plastic Surgery Palo Alto California United States 94306-3811
2 Premier Plastic Surgery San Mateo California United States 94401
3 Aesthetic Plastic Surgery New York New York United States 10025
4 Reviance Plastic Surgery & Aesthetics Center Clackamas Oregon United States 97015
5 Puget Sound Plastic Surgery Kirkland Washington United States 98033

Sponsors and Collaborators

  • Serene Medical Inc

Investigators

  • Study Director: Scott McGill, Vice President Product Development

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Serene Medical Inc
ClinicalTrials.gov Identifier:
NCT02466178
Other Study ID Numbers:
  • SM 14-01
First Posted:
Jun 9, 2015
Last Update Posted:
Mar 22, 2017
Last Verified:
Mar 1, 2017

Study Results

No Results Posted as of Mar 22, 2017